---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-228317"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:57:28.170415+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics elects Brian Posner as Class III director

## Summary
- Brian Posner elected to Board effective Oct 1, 2025; term runs until 2026 annual meeting.
- Posner deemed independent under Nasdaq rules; no committee appointments.
- Received option to purchase 70,000 shares at $12.50 strike, vesting monthly over three years.
- Annual cash compensation of $45,000 plus standard equity grants under director program.
- No family relationships or transactions with company officers.

## SEC filing metadata
- accession: 0001193125-25-228317
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312525228317/0001193125-25-228317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312525228317/dyn-20251001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-228317
- JSON: https://secwatch.observer/filing/0001193125-25-228317.json
- Plain text: https://secwatch.observer/filing/0001193125-25-228317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.